CAC
AST

Certified Advisory Corp’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Certified Advisory Corp’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1
Closed – – 817
2017
Q4 		$0 Buy
+1
New +$3 ﹤0.01% 730

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Certified Advisory Corp's AST Position: Q1 2018 in Review

Certified Advisory Corp sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2018, closing a stake of 1 share.

Certified Advisory Corp first reported a position in AST in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 72 funds tracked by Wall St. Rank hold AST as of Q1 2018.

  • Certified Advisory Corp reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2018 after selling out during the quarter.
  • Certified Advisory Corp sold 1 Asterias Biotherapeutics Inc. Series A share in Q1 2018.
  • Certified Advisory Corp first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2017 and held it in 1 quarter.
  • Certified Advisory Corp's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q4 2017.
  • 72 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2018.

Based on Certified Advisory Corp's 13F filing for Q1 2018, filed 30 Apr 2018.